Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Zepbound Tops Wegovy for Weight Loss
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease.Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.
Lilly invests $3 billion to expand Wisconsin plant
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Seeking Alpha on MSN
6h
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
Given the strong demand expected for
Eli
Lilly
's (NYSE:LLY) weight loss treatment
Zepbound
(tirzepatide) in the UK, the ...
6h
Eli Lilly’s $3 billion expansion in Kenosha County will mean 750 new jobs
Eli Lilly has announced a $3 billion expansion in Kenosha County to its manufacturing facility acquired earlier this year in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Tsunami warnings lifted
Images of suspect released
Set to return after 20 years
May cut diabetes risk
Recuses himself from case
Ethics report release blocked
Nadler to step aside
Billy Long to lead IRS
Winter storm to hit US
DOJ: Bias against Blacks
Satellites to create eclipses
Recalls over 205,000 SUVs
Social Security chief pick
US trade deficit shrinks
SpaceX sets record
Raw milk recall expands
Tops $100K for the first time
Taiwan's pres visits Guam
Medellin cartel leader freed
Syrian rebels capture Hama
$10B AI data center in LA
Rockefeller tree lights up
Weekly jobless claims rise
Prenatal test spots cancer?
Delays oil output hike
Airlines to pay for delays?
New AI tools for employees
Airbus layoffs
Jury deliberations continue
Meet with lawmakers
Related topics
Wegovy
Novo Nordisk
Amgen
Glucagon-like peptide-1
Feedback